Giant-cell arteritis and polymyalgia rheumatica
CM Weyand, JJ Goronzy - New England Journal of Medicine, 2014 - Mass Medical Soc
New England Journal of Medicine, 2014•Mass Medical Soc
Key Clinical Points Giant-Cell Arteritis and Polymyalgia Rheumatica The immune-mediated
diseases giant-cell arteritis and polymyalgia rheumatica occur in patients 50 years of age or
older and are now recognized as chronic conditions. The diagnosis of giant-cell arteritis
should be confirmed on the basis of histologic findings when possible. Glucocorticoids are
the standard therapy for both giant-cell arteritis and polymyalgia rheumatica, with higher
doses used for giant-cell arteritis. Disease flares in patients with giant-cell arteritis and …
diseases giant-cell arteritis and polymyalgia rheumatica occur in patients 50 years of age or
older and are now recognized as chronic conditions. The diagnosis of giant-cell arteritis
should be confirmed on the basis of histologic findings when possible. Glucocorticoids are
the standard therapy for both giant-cell arteritis and polymyalgia rheumatica, with higher
doses used for giant-cell arteritis. Disease flares in patients with giant-cell arteritis and …
Key Clinical Points
Giant-Cell Arteritis and Polymyalgia Rheumatica
- The immune-mediated diseases giant-cell arteritis and polymyalgia rheumatica occur in patients 50 years of age or older and are now recognized as chronic conditions.
- The diagnosis of giant-cell arteritis should be confirmed on the basis of histologic findings when possible.
- Glucocorticoids are the standard therapy for both giant-cell arteritis and polymyalgia rheumatica, with higher doses used for giant-cell arteritis.
- Disease flares in patients with giant-cell arteritis and polymyalgia rheumatica are common during the tapering of glucocorticoids and often respond to a 10 to 20% increase in dose.
- Arteritic ischemic optic neuropathy, which can result in blindness, should be treated as an emergency and requires prompt diagnosis and initiation of high-dose glucocorticoid therapy.
- In one quarter of patients with giant-cell arteritis, the aorta and its major branches are involved. Large-vessel disease is reliably diagnosed with computed tomography or magnetic resonance imaging.
- Longevity is generally not reduced by giant-cell arteritis or polymyalgia rheumatica, but glucocorticoid treatment often has adverse effects. Patients should be closely monitored, with attention to bone loss and consideration of prophylaxis against pneumocystis pneumonia.
The New England Journal Of Medicine